PCM
OKUR

Prelude Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Prelude Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
+46,692
New +$200K 0.02% 955
2024
Q2 		– Sell
-1,722
Closed -$28.6K – 1556
2024
Q1 		$28.6K Buy
+1,722
New +$28.4K ﹤0.01% 1272
2023
Q4 		– Sell
-1,480
Closed -$113K – 1409
2023
Q3 		$113K Hold
1,480
– – 0.01% 979
2023
Q2 		$97.1K Hold
1,480
– – 0.01% 936
2023
Q1 		$88.5K Buy
+1,480
New +$53.6K 0.01% 962

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prelude Capital Management's OKUR Position: Q2 2026 in Review

Prelude Capital Management opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 46,692 shares worth $213K. The stake represents 0.02% of the portfolio and ranks #955 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in OKUR as recently as Q1 2024.

Prelude Capital Management first reported a position in OKUR in Q1 2023 and has held it in 5 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Prelude Capital Management held 46,692 shares of OnKure Therapeutics worth $213K as of Q2 2026.
  • OnKure Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • OnKure Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #955 holding.
  • Prelude Capital Management first reported a position in OnKure Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.